These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 15225121)

  • 1. Lipoprotein transport in the metabolic syndrome: methodological aspects of stable isotope kinetic studies.
    Chan DC; Barrett PH; Watts GF
    Clin Sci (Lond); 2004 Sep; 107(3):221-32. PubMed ID: 15225121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in the investigation of lipoprotein metabolism using tracer methodology.
    Chan DC; Watts GF
    Clin Lab; 2006; 52(7-8):353-61. PubMed ID: 16955633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic regulation of apoB100 metabolism in insulin resistance in vivo.
    Watts GF; Ooi EM; Chan DC
    Pharmacol Ther; 2009 Sep; 123(3):281-91. PubMed ID: 19490928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipoprotein transport in the metabolic syndrome: pathophysiological and interventional studies employing stable isotopy and modelling methods.
    Chan DC; Barrett PH; Watts GF
    Clin Sci (Lond); 2004 Sep; 107(3):233-49. PubMed ID: 15225143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetic studies to investigate lipoprotein metabolism.
    Borén J; Taskinen MR; Adiels M
    J Intern Med; 2012 Feb; 271(2):166-73. PubMed ID: 22142374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apolipoprotein C-III: understanding an emerging cardiovascular risk factor.
    Ooi EM; Barrett PH; Chan DC; Watts GF
    Clin Sci (Lond); 2008 May; 114(10):611-24. PubMed ID: 18399797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fish oils, phytosterols and weight loss in the regulation of lipoprotein transport in the metabolic syndrome: lessons from stable isotope tracer studies.
    Watts GF; Chan DC; Ooi EM; Nestel PJ; Beilin LJ; Barrett PH
    Clin Exp Pharmacol Physiol; 2006 Sep; 33(9):877-82. PubMed ID: 16922825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies.
    Chan DC; Watts GF
    Expert Opin Pharmacother; 2011 Jan; 12(1):13-30. PubMed ID: 20629587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of weight loss on markers of triglyceride-rich lipoprotein metabolism in the metabolic syndrome.
    Chan DC; Watts GF; Ng TW; Yamashita S; Barrett PH
    Eur J Clin Invest; 2008 Oct; 38(10):743-51. PubMed ID: 18837799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipoprotein kinetics in the metabolic syndrome: pathophysiological and therapeutic lessons from stable isotope studies.
    Chan DC; Barrett PH; Watts GF
    Clin Biochem Rev; 2004 Feb; 25(1):31-48. PubMed ID: 18516204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The metabolic and pharmacologic bases for treating atherogenic dyslipidaemia.
    Chan DC; Barrett PH; Watts GF
    Best Pract Res Clin Endocrinol Metab; 2014 Jun; 28(3):369-85. PubMed ID: 24840265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interrelationships between human apolipoprotein A-I and apolipoproteins B-48 and B-100 kinetics using stable isotopes.
    Welty FK; Lichtenstein AH; Barrett PH; Dolnikowski GG; Schaefer EJ
    Arterioscler Thromb Vasc Biol; 2004 Sep; 24(9):1703-7. PubMed ID: 15242863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delayed in vivo catabolism of intermediate-density lipoprotein and low-density lipoprotein in hemodialysis patients as potential cause of premature atherosclerosis.
    Ikewaki K; Schaefer JR; Frischmann ME; Okubo K; Hosoya T; Mochizuki S; Dieplinger B; Trenkwalder E; Schweer H; Kronenberg F; Koenig P; Dieplinger H
    Arterioscler Thromb Vasc Biol; 2005 Dec; 25(12):2615-22. PubMed ID: 16195474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-density lipoprotein as a key component in the prevention of premature atherosclerotic disease in the insulin resistance syndrome.
    Hansel B; Kontush A; Twickler MT
    Semin Vasc Med; 2004 May; 4(2):215-23. PubMed ID: 15478044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor?
    Chan DC; Chen MM; Ooi EM; Watts GF
    Int J Clin Pract; 2008 May; 62(5):799-809. PubMed ID: 18201179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microsomal triglyceride transfer protein -493T variant reduces IDL plus LDL apoB production and the plasma concentration of large LDL particles.
    Lundahl B; Skoglund-Andersson C; Caslake M; Bedford D; Stewart P; Hamsten A; Packard CJ; Karpe F
    Am J Physiol Endocrinol Metab; 2006 Apr; 290(4):E739-45. PubMed ID: 16291571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin resistance, the insulin resistance syndrome, and cardiovascular disease.
    Reaven GM
    Panminerva Med; 2005 Dec; 47(4):201-10. PubMed ID: 16489319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dietary plant sterols supplementation does not alter lipoprotein kinetics in men with the metabolic syndrome.
    Ooi EM; Watts GF; Barrett PH; Chan DC; Clifton PM; Ji J; Nestel PJ
    Asia Pac J Clin Nutr; 2007; 16(4):624-31. PubMed ID: 18042521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adiponectin is an important determinant of apoA-I catabolism.
    Vergès B; Petit JM; Duvillard L; Dautin G; Florentin E; Galland F; Gambert P
    Arterioscler Thromb Vasc Biol; 2006 Jun; 26(6):1364-9. PubMed ID: 16574896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease.
    Lara-Castro C; Fu Y; Chung BH; Garvey WT
    Curr Opin Lipidol; 2007 Jun; 18(3):263-70. PubMed ID: 17495599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.